AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north ...

Eight New Jersey-based companies have earned spots on U.S. News & World Report’s 2024 list of “Best Companies to Work For." ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences. Global biotech spending ...

London-based lender Zvilo has increased its debt facility with Fasanara Capital to €75M, up from its original commitment in ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

A daily rundown of the economic reports and corporate earnings that will be grabbing the market’s attention in the week ahead ...

Morning. Today, we discuss how Duchenne patients and their families are responding to the shelving of Sarepta Therapeutics’ ...

Cytokinetics stock garners strong analyst support with high growth potential. Click here to find out why the CYTK's pipeline ...

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.